ZIM Laboratories Limited

ZIM Laboratories Limited (ZIM) has been listed on the BSE Main Board on June 8, 2018. The book value price of ZIM was Rs 160 per equity share. Anwar Daud, Chairman & Managing Director, told media persons here recently that ZIM is amongst the few global companies to have developed and commercialized the oral film technology, besides also being the first Indian company to manufacture multi-layer thin films that contain more than one API on a single thin strip. Describing ZIM Laboratories as a unique R&D-centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary Novel Drug Delivery Solutions (NDDS), he said ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines and the company listing on BSE on June 8 had a price discovery as per trading on the bourses. Original Article

ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS). Promoted by Technocrat Dr. Anwar Daud, the company has a Unique R&D focused business model helping customers with product development, co-development, out licensing, manufacturing, supplies and marketing support with a strong IP base – 26 inventions with 53 patent filings and 174 clients across 45 countries. Original Article  

ZIM is amongst a few companies globally to have developed and commercialized the oral film technology. The first Indian company to manufacture multi-layer thin films - that contain more than one API on a single thin strip. Company to get listed on BSE Mainboard on June 08, 2018. The book value price of ZIM is Rs.160/- per equity share. ZIM got listed on OTC Exchange on India in 1994, following the SEBI guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary Novel Drug Delivery Solutions (NDDS). Original Article  

ZIM is amongst a few companies globally to have developed and commercialized the oral film technology. The first Indian company to manufacture multi-layer thin films – that contain more than one API on a single thin strip. Company to get listed on BSE Mainboard on June 08, 2018 . The book value price of ZIM is Rs. 160/-  per equity share ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS). ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. Original Article

Nagpur-based pharmaceuticals company Zim Laboratories will list on BSE on Friday, June 8. Zim Labs was trading on the OTC Exchange Of India before the Securities Exchange Board of India (SEBI) withdrew its recognition of it in March 2015. The company was recently by allowed SEBI to list on the main board of BSE.  This listing will provide an exit to some of its existing shareholders. The book value of Zim Labs, promoted by Anwar Daud, is Rs 160 per equity share. Daud and his family own 54 percent stake in the company, and private equity firm Ashmore Alchemy India Advisors owns around 22 percent. The rest is owned by minority shareholders. Original Article  

ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS). ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. Promoted by Technocrat Dr. Anwar Daud, the company has a Unique R&D focused business model helping customers with product development, co-development, out licensing, manufacturing, supplies and marketing support with a strong IP base – 26 inventions with 53 patent filings and 174 clients across 45 countries. Original Article  

The company was allowed recently by SEBI to list on the BSE main board. This listing will provide an exit to existing shareholders. Original Article  

ZIM Laboratories  (ZIM), an R&D centred pharmaceutical company today  said it will list its shares on BSE on Friday. ZIM got listed on  OTC Exchange of India  in 1994, following the Sebi guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. The book value price is Rs 160 per equity share. Original Article

Zim Laboratories Limited partners with India's leading Pharma  Business Magazine, Express Pharma.  Following the successful first edition of Formulation and Drug Delivery (FDD) Conclave, The Indian Express (P) Ltd and Express Pharma – India’s leading Pharma Business Magazine have designed an even more rewarding experience. With the theme ‘ Expanding Horizons of FDD Research: Embracing complexity ’, the second edition of FDD Conclave takes a deeper dive into evolving regulations which are fundamental to the FDD scientists' role as key gatekeepers of a company's future reputation and market leadership. Original Article

Drug companies are moving up the value chain, transforming into complex generic manufacturers with high end R&D facilities. Nagpur-based Zim Laboratories is a non-descript drug company with turnover in excess of Rs 250 crore. In the past two decades, Zim has been silently working on developing innovative and differentiated pharmaceutical products or specialty generic complex drugs. Recently, it developed a new product, Orally Disintegrating Strip (ODS) formulations up to 100 milligram, based on a patented oral thin film technology. These films, when placed on the tongue, adhere to the tongue mucosa and disintegrate almost instantaneously. There are only some 10 companies across the globe with this technology, but they are not able to grab a big share of the market due to prohibitive manufacturing costs. "With our technology, we can offer thin films at a price near to that of an oral tablet," says Anwar S. Daud, Managing Director of Zim Laboratories. Original Article ...

African Union (AU) is coming up with an African Medicine Agency (AMA) which will be tasked with cooperation and strengthening of healthcare activities to harmonize medicine regulation of member states of the Union in line with European Medicine Agency (EMA). There are 55 countries in African Union. In August 2017 AU had come up with draft treaty for the establishment of AMA. Once the draft treaty is ratified by the member states, it will pave the way for setting up of AMA. The main objective of AMA is to improve access to quality, safe and efficacious medical products on the continent through coordination and strengthening of ongoing initiatives to harmonize medicines regulation, promote cooperation and mutual recognition of regulatory decisions. Besides, it will be carrying out regulatory oversight of selected medical products and providing technical guidance to AU member states and Regional Economic Community (RECs) recognized by AU, pooling expertise and capacities and strength...